Drug Profile
Research programme: SAS1B targeted antibody-drug conjugates - Neoantigenics
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Neoantigenics
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Aug 2016 Preclinical trials in Cancer in USA (unspecified route)